Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer

NCT06395753 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT06395753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06395753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer
Lead sponsor
Debiopharm International SA
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2024
Completion date
July 22, 2026
Enrollment
55 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer